At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics

ASCO 2023 – McCormick Place, In advance of a new Current Procedural Terminology (CPT) Category III code that will go into effect Perthera, the leader in AI precision oncology solutions, introduced its latest generation of clinical support tools, including Perthera Lab Direct and Perthera RWE Navigator. As part of this new, enhanced clinician experience, Perthera Lab Direct will make it easier to order reports, delivering results faster and the Perthera RWE Navigator will provide clinicians direct access to Perthera’s powerful analytics. The Category III CPT code provides a critical pathway to reimbursement and wider adoption of AI-assisted Oncology decision support. The new multi-ordering platform and expanded analytics bench are intended to help support increased clinician demand.

Recommended: Embrace AI to become a W.I.T.C.H. Leader

“As we continue to scale the business, providing world-class support to physicians is a paramount goal to ensure all have access to our AI-assisted Oncology decision support”, said Albert Kelley, President and CEO of Perthera. These resources can be found on Perthera’s re-designed website where physicians and their staff can log on to gain access. Perthera Lab Direct streamlines the ordering process, working more seamlessly into the oncologist’s office workflow, and linking directly to lab results so a Perthera Report can be delivered faster and with less effort. The Perthera RWE Navigator provides physicians with tools to analyze their own patient population to inform their future treatment decisions, research studies, or evaluate reimbursement issues. “We are committed to investing in building better—better systems, better experiences, and continued advancement of our AI platform-—to help drive and support wide adoption”, said Donna Tuths, Board Chair of Perthera.

Recommended: AiThority Interview with Arijit Sengupta, CEO and Founder at Aible

Perthera’s patented AI Precision Oncology Engine is based on over 10 years of industry-defining research that uniquely combines a patient’s past medical and treatment history, and their multi-omic profile to produce ranked therapy options predicted to have the best outcome for that patient. The platform has been shown in peer-reviewed research to significantly improve patient survival. “Our ongoing research is focused on deepening our science and understanding of the complex set of key drivers that impact patient response to treatment. Helping physicians to get the best outcome for their patients is our mission”, said Dr. Emmanuel “Chip” Petricoin, Founder and Chief Scientist at Perthera. Dr. Edik Blais, Vice President of Research at Perthera will present the latest research related to the prediction of treatment sequencing in a poster session to be held in Hall A, Poster Board #470 from 8-11 am on June 5^th.

Top AI ML Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab

[To share your insights with us, please write to sghosh@martechseries.com]

The post At ASCO ’23, AI Precision Oncology Company Perthera Unveils Premium Experience for Clinicians with New Options for Ordering and Access to Enhanced Perthera Analytics appeared first on AiThority.

ai
medical